Effectiveness of circulating tumor DNA for detection of KRAS gene mutations in colorectal cancer patients: A meta-analysis

OncoTargets and Therapy

Volumn 10, Issue , 2017, Pages 945-953

  Hao, Yi Xin ^a   Fu, Qiang ^b   Guo, Yan Yan ^a   Ye, Ming ^a   Zhao, Hui Xia ^a   Wang, Qi ^a   Peng, Xiu Mei ^a   Li, Qiu Wen ^a   Wang, Ru Liang ^a   Xiao, Wen Hua ^a  

^a Department of Respiratory Medicine First Affiliated Hospital Soochow Utiiversity   (China)

^b People Liberation Army General Hospital   (China)

Author keywords

Cancer; Circulating tumor DNA; KRAS; Mutation

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; CIRCULATING TUMOR DNA; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GENE IDENTIFICATION; GENE MUTATION; HUMAN; META ANALYSIS; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TRUE NEGATIVE RESULT; TRUE POSITIVE RESULT; TUMOR GENE; VALIDATION STUDY;

EID: 85013499993     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S123954     Document Type: Article

References (40)

1. Centers of Diseases Control and Prevention. Health Status and Determinants. Life Expectancy and Mortality. 2015. Available from: http://www.cdc.gov/nchs/data/hus/hus15.pdf#019. Accessed May 1, 2016.
2. National Comprehensive Cancer Network [webpage on the Internet]. Guidelines for Detection, Prevention, & Risk Reduction. 2017. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed December 24, 2016.
3. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006;24(31):5034-5042.
4. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169-181.
5. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncology. 2005;6(5):279-286.
6. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757-1765.
7. Hol L, de Jonge V, van Leerdam ME, et al. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. Eur J Cancer. 2010;46(11):2059-2066.
8. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883-892.
9. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646-650.
10. Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev. 1999;18(1):65-73.
11. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res. 2007;635(2-3):105-117.
12. Koyanagi K, Mori T, O’Day SJ, Martinez SR, Wang HJ, Hoon DS. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res. 2006;66(12):6111-6117.
13. Mori T, O’Day SJ, Umatani N, et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol. 2005;23(36):9351-9358.
14. Qiu M, Wang J, Xu Y, et al. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2015;24(1):206-212.
15. Thierry AR, Mouliere F, El Messaoudi S, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20(4):430-435.
16. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.
17. Danese E, Minicozzi AM, Benati M, et al. Comparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with colorectal cancer. PLoS One. 2015;10(5):e0126417.
18. Kim ST, Chang WJ, Jin L, Sung JS, Choi YJ, Kim YH. Can serum be used for analyzing the KRAS mutation status in patients with advanced colorectal cancer? Cancer Res Treat. 2015;47(4):796-803.
19. Kopreski MS, Benko FA, Borys DJ, Khan A, McGarrity TJ, Gocke CD. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J Natl Cancer Inst. 2000;92(11):918-923.
20. Kuo YB, Chen JS, Fan CW, Li YS, Chan EC. Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. Clin Chim Acta. 2014;433:284-289.
21. Lefebure B, Charbonnier F, Di Fiore F, et al. Prognostic value of circulating mutant DNA in unresectable metastatic colorectal cancer. Ann Surg. 2010;251(2):275-280.
22. Lin JK, Lin PC, Lin CH, et al. Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors. Ann Surg Oncol. 2014;21(suppl 4):S680-S686.
23. Liu P, Liang H, Xue L, et al. Potential clinical significance of plasma-based KRAS mutation analysis using the COLD-PCR/TaqMan(®) -MGB probe genotyping method. Exp Ther Med. 2012;4(1): 109-112.
24. Miyano S, Hanazawa K, Kitabatake T, Fujisawa M, Kojima K. Detecting KRAS mutations in peripheral blood of colorectal cancer patients by peptide nucleic acid clamp PCR. Exp Ther Med. 2012;4(5):790-794.
25. Morgan SR, Whiteley J, Donald E, et al. Comparison of KRAS mutation assessment in tumor DNA and circulating free DNA in plasma and serum samples. Clin Med Insights Pathol. 2012;5:15-22.
26. Mulcahy HE, Lyautey J, Lederrey C, et al. Plasma DNA K-ras mutations in patients with gastrointestinal malignancies. Ann N Y Acad Sci. 2000;906:25-28.
27. Perrone F, Lampis A, Bertan C, et al. Circulating free DNA in a screening program for early colorectal cancer detection. Tumori. 2014;100(2):115-121.
28. Pu X, Pan Z, Huang Y, et al. Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: biological and clinical implications. Oncol Lett. 2013;5(1):249-254.
29. Ryan BM, Lefort F, McManus R, et al. A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up. Gut. 2003;52(1):101-108.
30. Sakai K, Tsurutani J, Yamanaka T, et al. Extended RAS and BRAF mutation analysis using next-generation sequencing. PLoS One. 2015;10(5):e0121891.
31. Sefrioui D, Sarafan-Vasseur N, Beaussire L, et al. Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer. Dig Liver Dis. 2015;47(10):884-890.
32. Spindler KL, Pallisgaard N, Andersen RF, Brandslund I, Jakobsen A. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer. PLoS One. 2015;10(4):e0108247.
33. Taly V, Pekin D, Benhaim L, et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem. 2013;59(12):1722-1731.
34. Xu JM, Liu XJ, Ge FJ, et al. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer. J Exp Clin Cancer Res. 2014;33:104.
35. Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev. 1994;3(1):67-71.
36. Vasioukhin V, Anker P, Maurice P, Lyautery J, Lederrey C, Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol. 1994;86(4):774-779.
37. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58(9):882-893.
38. Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988;240(4857):1285-1293.
39. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985-990.
40. Nygaard AD, Spindler KG, Pallisgaard N, Anderson RF, Jakobsen A. Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC. Oncol Rep. 2014;31:969-974.